{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:51:48Z","timestamp":1769597508820,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.seizure.2018.03.013","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T12:48:58Z","timestamp":1523450938000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children"],"prefix":"10.1016","volume":"58","author":[{"given":"Nafiye Polat","family":"\u00c7i\u00e7ek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fclay","family":"Kama\u015fak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-1048","authenticated-orcid":false,"given":"Mine","family":"Serin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysenur","family":"Okten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Cansu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.seizure.2018.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2007.04.001","article-title":"Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions","volume":"75","author":"Hamed","year":"2007","journal-title":"Epilepsy Res"},{"issue":"13","key":"10.1016\/j.seizure.2018.03.013_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/00002018-200124130-00004","article-title":"Bodyweight gain and anticonvulsants: a comparative review","volume":"24","author":"Jallon","year":"2001","journal-title":"Drug Saf"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2018.03.013_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-1211(03)00091-3","article-title":"Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients","volume":"55","author":"Luef","year":"2003","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.seizure.2018.03.013_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"Verrotti","year":"2011","journal-title":"Obes Rev"},{"issue":"8","key":"10.1016\/j.seizure.2018.03.013_bib0025","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0883073809349461","article-title":"Weight gain and insulin resistance in children treated with valproate: the influence of time","volume":"25","author":"Masuccio","year":"2010","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2018.03.013_bib0030","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.0013-9580.2004.66303.x","article-title":"Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy","volume":"45","author":"El-Khayat","year":"2004","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2018.03.013_bib0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/088307380201700405","article-title":"Insulin resistance in epileptic girls who gain weight after therapy with valproic acid","volume":"17","author":"Verrotti","year":"2002","journal-title":"J Child Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2018.03.013_bib0040","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/0269881108091595","article-title":"Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial","volume":"23","author":"Martin","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.013_bib0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2018.03.013_bib0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pediatrneurol.2008.05.006","article-title":"Lack of valproic acid-associated weight gain in prepubertal children","volume":"39","author":"Espinosa","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2018.03.013_bib0055","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/oby.2005.161","article-title":"Weight change in monozygotic twins treated with valproate","volume":"13","author":"Klein","year":"2005","journal-title":"Obes Res"},{"issue":"6","key":"10.1016\/j.seizure.2018.03.013_bib0060","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ejpn.2014.07.004","article-title":"Endocrine effects of valproic acid therapy in girls with epilepsy: a prospective study","volume":"18","author":"Goldberg-Stern","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2018.03.013_bib0065","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000375374","article-title":"Endocrine effects of valproate versus carbamazepine in males with epilepsy. A prospective study","volume":"83","author":"Goldberg-Stern","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"10.1016\/j.seizure.2018.03.013_bib0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"Pylv\u00e4nen","year":"2006","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2018.03.013_bib0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00228-007-0318-0","article-title":"Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes","volume":"63","author":"Khazaal","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2018.03.013_bib0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebcm.2005.09.041","article-title":"Topiramate may help reduce weight and blood pressure in obese people. Commentary","volume":"9","author":"Halpern","year":"2005","journal-title":"Evid Based Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.seizure.2018.03.013_bib0085","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"5","key":"10.1016\/j.seizure.2018.03.013_bib0090","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.2007.136929","article-title":"Topiramate, nutrition and weight change: a prospective study","volume":"79","author":"Klein","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.seizure.2018.03.013_bib0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.seizure.2003.12.001","article-title":"Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients\u2013a retrospective analysis","volume":"13","author":"Reiter","year":"2004","journal-title":"Seizure"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2018.03.013_bib0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2008.11.014","article-title":"Topiramate weight loss in migraine patients","volume":"278","author":"Alberici","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.seizure.2018.03.013_bib0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/NDT.S3420","article-title":"Treatment of obese patients with binge eating disorder using topiramate: a review","volume":"5","author":"Leombruni","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"10.1016\/j.seizure.2018.03.013_bib0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.seizure.2013.07.007","article-title":"The effects of topiramate and valproate therapy on insulin, cpeptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy","volume":"22","author":"Sonmez","year":"2013","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2018.03.013_bib0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpn.2008.05.005","article-title":"States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain","volume":"13","author":"Hamed","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2018.03.013_bib0120","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/0883073808319072","article-title":"Does ghrelin really increase in epileptic children treated with valproate?","volume":"23","author":"Aydin","year":"2008","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2018.03.013_bib0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1528-1167.2009.02307.x","article-title":"Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid","volume":"51","author":"Prodam","year":"2010","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2018.03.013_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000327367","article-title":"Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate","volume":"76","author":"Cansu","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"10.1016\/j.seizure.2018.03.013_bib0135","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/08830738050200101501","article-title":"Cinazeptin, and neuropeptide Y levels in epileptic children treated with valproate","volume":"20","author":"Aydin","year":"2005","journal-title":"J Child Neurol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117306222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117306222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:51:54Z","timestamp":1761011514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117306222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":27,"alternative-id":["S1059131117306222"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.03.013","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}